We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search


Firm name


1,411 results found


Bass, Berry & Sims PLC | USA | 2 Aug 2019

Key Takeaways from CMS’ New Proposed Rule on Stark Law Advisory Opinions

While the industry awaits more sweeping value-based related changes to the Stark Law regulations, on July 29, 2019, the Centers for Medicare &


Blank Rome LLP | USA, Canada | 1 Aug 2019

Will HHS’s Safe Importation Action Plan Affect How the Federal Government Purchases Drugs?

On July 31, the Department of Health and Human Services (“HHS”) and the Food and Drug Administration (“FDA”) announced their


Sheppard Mullin Richter & Hampton LLP | USA | 25 Jul 2019

Is Prescription Drug Pricing The Cure For Partisanship?

In a rare act of bipartisanship, Senate Finance Committee Chairman Chuck Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Ore., introduced on July


Manatt Phelps & Phillips LLP | USA | 22 Jul 2019

Healthcare Price Transparency: Implications for Providers and Payers

On June 24, 2019, President Donald Trump issued an “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put


Quarles & Brady LLP | USA | 9 Jul 2019

340B Litigation Updates and Other Program Developments

In the latest development of the ongoing 340B Medicare Part B payment reduction controversy, US District Judge Rudolph Contreras again concluded that


Morgan Lewis | USA | 2 Jul 2019

Will Hospitals and Insurers Have to Disclose Their Contracted Rates to Consumers Under Executive Order?

US President Donald Trump issued the Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First on June


Manatt Phelps & Phillips LLP | USA | 25 Jun 2019

The Final Rule’s Impact on Drug Pricing Transparency

On May 8, the administration issued the much-anticipated final rule requiring drug manufacturers to disclose wholesale acquisition prices in their


Brownstein Hyatt Farber Schreck LLP | USA | 21 Jun 2019

Medicare Rulemaking After Azar v. Allina Health Services

The Medicare Program, established in 1965, initially seemed simple: provide health care for senior citizens by paying hospitals and doctors directly


FisherBroyles LLP | USA | 18 Jun 2019

Chiedi Takes Over as HHS Inspector General - Promises Aggressive Enforcement

On June 1, Joanne Chiedi assumed the role of Acting Inspector General at the U.S. Department of Health and Human Services following the departure of


McGuireWoods Consulting LLC | USA | 10 Jun 2019

Supreme Court Rules HHS Cannot Take Short-Cuts in Rulemaking

In a 7-to-1 decision, the U.S. Supreme Court on June 3, 2019, held that “Because the Department of Health and Human Services neglected its statutory

Previous page 1 2 3 ...